Your browser doesn't support javascript.
loading
Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease.
Rydz, Agnieszka; Lange, Magdalena; Lugowska-Umer, Hanna; Sikorska, Monika; Nowicki, Roman J; Morales-Cabeza, Cristina; Alvarez-Twose, Iván.
Affiliation
  • Rydz A; Student's Scientific Circle Practical and Experimental Dermatology, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Lange M; Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Lugowska-Umer H; Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Sikorska M; Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Nowicki RJ; Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Morales-Cabeza C; Instituto de Estudios de Mastocitosis de Castilla-La Mancha (CLMast)-Spanish Reference Center for Mastocytosis, Hospital Virgen del Valle-Complejo Hospitalario Universitario de Toledo, 45071 Toledo, Spain.
  • Alvarez-Twose I; Instituto de Estudios de Mastocitosis de Castilla-La Mancha (CLMast)-Spanish Reference Center for Mastocytosis, Hospital Virgen del Valle-Complejo Hospitalario Universitario de Toledo, 45071 Toledo, Spain.
Int J Mol Sci ; 25(3)2024 Jan 23.
Article in En | MEDLINE | ID: mdl-38338679
ABSTRACT
Mastocytosis is a heterogeneous disease characterized by the expansion and accumulation of neoplastic mast cells in various tissues. Diffuse cutaneous mastocytosis (DCM) is a rare and most severe form of cutaneous mastocytosis, which typically occurs in childhood. There have been reports of a familial DCM with specific gene mutations, indicating both sporadic and hereditary factors involved in its pathogenesis. DCM is associated with severe MC mediator-related symptoms and an increased risk of anaphylaxis. The diagnosis is based on the appearance of skin lesions, which typically show generalized thickening, erythroderma, blistering dermographism, and a positive Darier's sign. Recognition, particularly in infants, is challenging due to DCMs resemblance to other bullous skin disorders. Therefore, in unclear cases, a skin biopsy is crucial. Treatment focuses on symptom management, mainly including antihistamines and mast cell stabilizers. In extremely severe cases, systemic steroids, tyrosine kinase inhibitors, phototherapy, or omalizumab may be considered. Patients should be equipped with an adrenaline autoinjector. Herein, we conducted a comprehensive review of literature data on DCM since 1962, which could help to better understand both the management and prognosis of DCM, which depends on the severity of skin lesions, intensity of mediator-related symptoms, presence of anaphylaxis, and treatment response.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Erythematosus, Cutaneous / Mastocytosis / Mastocytosis, Cutaneous / Anaphylaxis Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies Limits: Humans / Infant Language: En Journal: Int J Mol Sci Year: 2024 Type: Article Affiliation country: Poland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Erythematosus, Cutaneous / Mastocytosis / Mastocytosis, Cutaneous / Anaphylaxis Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies Limits: Humans / Infant Language: En Journal: Int J Mol Sci Year: 2024 Type: Article Affiliation country: Poland